ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.60
0.71%
US Tech 100
19,636.04
0.55%
S&P 500
5,770.20
0.55%
US Dollar vs CAD
1.43715
0.00%
Bitcoin
86,219.65
0.08%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Arvinas Inc (ARVN) Share Price

Arvinas Inc

Arvinas Inc (ARVN)

NASDAQ
18.28
0.22
(1.22%)
Closed March 08 3:00PM
Delayed by 15 minutes
18.30
0.02
(0.11%)
After Hours: 6:59PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
18.30
Bid
12.00
Ask
28.00
Volume
1,912,001
17.76 Day's Range 18.76
15.53 52 Week Range 49.76
Market Cap
1.259B
Previous Close
18.06
Open
17.97
Last Trade
7
@
18.48
Last Trade Time
Financial Volume
US$ 35,059,548
VWAP
18.3366
Average Volume (3m)
1,071,326
Shares Outstanding
68,771,867
Dividend Yield
-
PE Ratio
-6.32
Earnings Per Share (EPS)
-2.89
Revenue
263.4M
Net Profit
-198.9M

About Arvinas Inc

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arvinas.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Arvinas Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARVN. The last closing price for Arvinas was US$18.06. Over the last year, Arvinas shares have traded in a share price range of US$ 15.53 to US$ 49.76.

Arvinas currently has 68,771,867 shares outstanding. The market capitalization of Arvinas is US$1.24 billion. Arvinas has a price to earnings ratio (PE ratio) of -6.32.

Ask ADVFN Intelligence (AI)

Arvinas (ARVN) Options Flow Summary

ARVN Options Flow

Overall Flow

Bullish

Net Premium

291k

Calls / Puts

400.00%

Buys / Sells

150.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ARVN Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 25 2025
ARVN (1.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 25 2025
ARVN (1.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 25 2025
ARVN (1.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 25 2025
ARVN (1.22%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 24 2025
ARVN (1.22%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 24 2025
ARVN (1.22%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 24 2025
ARVN (1.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 18 2025
ARVN (1.22%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 18 2025
ARVN (1.22%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.247.2684642438517.0618.9315.53123478017.21219595CS
4-0.81-4.2386185243319.1120.376215.53133448317.7303786CS
12-1.43-7.2478459199219.732115.53107132618.20697874CS
26-6.11-25.030725112724.4129.610615.5381841921.14949969CS
52-27.92-60.406750324546.2249.7615.5377935626.07929151CS
156-46.64-71.820141669264.9475.389913.5760243932.28496172CS
260-27.17-59.753683747545.47108.46513.5757888142.8547878CS

ARVN - Frequently Asked Questions (FAQ)

What is the current Arvinas share price?
The current share price of Arvinas is US$ 18.30
How many Arvinas shares are in issue?
Arvinas has 68,771,867 shares in issue
What is the market cap of Arvinas?
The market capitalisation of Arvinas is USD 1.24B
What is the 1 year trading range for Arvinas share price?
Arvinas has traded in the range of US$ 15.53 to US$ 49.76 during the past year
What is the PE ratio of Arvinas?
The price to earnings ratio of Arvinas is -6.32
What is the cash to sales ratio of Arvinas?
The cash to sales ratio of Arvinas is 4.78
What is the reporting currency for Arvinas?
Arvinas reports financial results in USD
What is the latest annual turnover for Arvinas?
The latest annual turnover of Arvinas is USD 263.4M
What is the latest annual profit for Arvinas?
The latest annual profit of Arvinas is USD -198.9M
What is the registered address of Arvinas?
The registered address for Arvinas is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Arvinas website address?
The website address for Arvinas is www.arvinas.com
Which industry sector does Arvinas operate in?
Arvinas operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
US$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
618.03M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
476.73M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
333.91M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
140.23M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
140.05M

ARVN Discussion

View Posts
Mr.Mister Mr.Mister 3 days ago
Data imminent
👍️0
Monksdream Monksdream 6 months ago
ARVN at a bottom channel
👍️0
Monksdream Monksdream 1 year ago
ARVN new 52=week high
👍️0
Monksdream Monksdream 1 year ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 1 year ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 1 year ago
ARVN new 52 week high
👍️0
crudeoil24 crudeoil24 4 years ago
ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”
👍️0
biocqr biocqr 5 years ago
Advantages of PROTACs vs. inhibition...

message_id=152832655
👍️0
G-lupo G-lupo 5 years ago
Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25
👍️0
boo boo boo boo 5 years ago
Starting to see a chink in the armor!
👍️0
G-lupo G-lupo 5 years ago
Possibly wall at 30.50
👍️0
G-lupo G-lupo 5 years ago
I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price
👍️0
boo boo boo boo 5 years ago
The offering:

8-k
👍️0
boo boo boo boo 5 years ago
Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!
👍️0
boo boo boo boo 5 years ago
It doesn't have to be a PR:

#8
👍️0
G-lupo G-lupo 5 years ago
Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30
👍️0
boo boo boo boo 5 years ago
https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/
👍️0
G-lupo G-lupo 5 years ago
When did they Do a price target announcement? I didn’t see that.
👍️0
boo boo boo boo 5 years ago
If I were in this one (I'm not), I'd be finding the exit on the price target announcement.
👍️0
G-lupo G-lupo 5 years ago
Arvn looking good, defintely see $26-27
👍️0
G-lupo G-lupo 5 years ago
What you mean IBD?
👍️0
boo boo boo boo 5 years ago
Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...
👍️0
G-lupo G-lupo 5 years ago
I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul
👍️0
boo boo boo boo 5 years ago
Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.
👍️0
G-lupo G-lupo 5 years ago
What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60
👍️0
boo boo boo boo 5 years ago
Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!
👍️0
boo boo boo boo 5 years ago
Fook R's!

EOM
👍️0
boo boo boo boo 5 years ago
Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!
👍️0
PennyStock Alert PennyStock Alert 6 years ago
ARVN
👍️0
G-lupo G-lupo 6 years ago
This stock very volatile, no rhyme or reason why it’s been up and down.
👍️0
morokoy morokoy 6 years ago
Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/
👍️0

Your Recent History

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads